Oragenics, Inc

Oragenics, Inc

Biotechnology

Tampa, FL 1,568 followers

Our mission is focused on developing vaccines to prevent and treat today’s and tomorrow’s infections.

About us

Oragenics, Inc. is a development-stage company dedicated to fighting infectious diseases, including those caused by coronaviruses and multidrug-resistant organisms. Its lead product is NT-CoV2-1, an intranasal vaccine candidate to prevent COVID-19 and variants of the SARS-CoV-2 virus. The NT-CoV2-1 program leverages coronavirus spike protein research licensed from the NIH and the NRC with a focus on reducing viral transmission and offering a more patient-friendly intranasal administration. Its lantibiotics program features a novel class of antibiotics against bacteria that have developed resistance to commercial antibiotics. For more information about Oragenics, please visit www.oragenics.com.

Industry
Biotechnology
Company size
11-50 employees
Headquarters
Tampa, FL
Type
Public Company
Specialties
probiotcs

Locations

Employees at Oragenics, Inc

Similar pages

Browse jobs

Funding

Oragenics, Inc 18 total rounds

Last Round

Post IPO equity

US$ 4.5M

See more info on crunchbase